Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma

MLA

Michinori Ogura, et al. “Phase 1 Study in Japan of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.” International Journal of Hematology, vol. 101, Feb. 2015, pp. 286–94. EBSCOhost, https://doi.org/10.1007/s12185-015-1743-y.

APA

Michinori Ogura, Masafumi Taniwaki, Kiyoshi Ando, Junya Kuroda, Tatsuya Suzuki, Yu Abe, Dai Maruyama, Kensei Tobinai, Koho Iizuka, Kenshi Suzuki, Meguru Achira, & Minoru Kojima. (2015). Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. International Journal of Hematology, 101, 286–294. https://doi.org/10.1007/s12185-015-1743-y

Chicago

Michinori Ogura, Masafumi Taniwaki, Kiyoshi Ando, Junya Kuroda, Tatsuya Suzuki, Yu Abe, Dai Maruyama, et al. 2015. “Phase 1 Study in Japan of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.” International Journal of Hematology 101 (February): 286–94. doi:10.1007/s12185-015-1743-y.